Kanda T.,Chiba University |
Imazeki F.,Chiba University |
Mikami S.,Kikkoman Hospital |
Kato K.,Red Cross |
And 13 more authors.
Advanced chronic hepatitis C patients with sustained virolological response by antivirals remain at risk for hepatocellular carcinoma (HCC). We investigated the incidence of HCC during and immediately after peginterferon-alfa-2a and ribavirin (RBV) treatment in patients with chronic hepatitis C in Japan. HCC was detected in 8 of 238 patients during and after these treatments (mean follow-up period: 572 ± 252 days). In conclusion, occurrence of HCC is not a rare event during and immediately after peginterferon-alfa-2a plus RBV treatment. In cases with cirrhosis, higher α-fetoprotein levels, old age, or a previous history of HCC treatment, clinicians should be especially alert for the possible development of HCC during and immediately after peginterferon-alfa-2a and RBV treatment. Clinicians should regularly check for the possible development of HCC even in chronic hepatitis C patients under treatment. Copyright © 2011 S. Karger AG, Basel. Source
Sato E.,Shin Matsudo Central General Hospital |
Sato E.,Dokkyo Medical University |
Amaha M.,Shin Matsudo Central General Hospital |
Nomura M.,Shin Matsudo Central General Hospital |
And 3 more authors.
Diabetes Research and Clinical Practice
Aims: Low-density lipoprotein (LDL)-apheresis removes various molecules including LDL/oxidized LDL and inflammatory cytokines and recovers clinical laboratory parameters. It is not yet known whether these advantages of LDL-apheresis improve the prognosis of patients with diabetic nephropathy accompanied by nephrotic syndrome. Methods: In this study, three groups of patients were retrospectively surveyed in a single center, and followed for approximately 3 years: an LDL-apheresis cohort (LDL-a; N = 20); a control cohort meeting the selection criterion of severe proteinuria ≥3. g/24. h (control-All; N = 55); and a subgroup of control-All with more severe proteinuria ≥5. g/24. h (control-mSP; N = 10), and evaluated the outcomes as survival and renal dysfunction and death/renal dysfunction free rate. Results: Death/renal dysfunction free rate was significantly higher in LDL-a than control-All (χ2=4.50; P=0.03) and control-mSP (χ2=27.68; P<0.001). Conclusion: These results suggest the possibilities which LDL-apheresis is considered to contribute to survival extension and renal function maintenance of severe diabetic nephropathy patients. © 2014 The Authors. Source